论文部分内容阅读
美国食品与药品监督管理局(FDA)于1月28日批准了Halaven(eribulin mesylate,甲磺酸艾日布林)用于治疗不能手术切除或晚期(转移性)脂肪肉瘤患者,该药物被获准用于曾接受含有蒽环类药物化疗的患者。FDA药品评价与研究中心血液与肿瘤学产品办公室主任称,Halaven是首个获准用于脂肪肉瘤的药物,该药物被证实可改善患者生存时间。FDA审评的临床实验数据表明,Halaven可延长总体生存期约7个月,为患者提供了具有临床意义的药物。软组织肉瘤(STS)是一种癌细胞生长在体内软组织中的疾病,包括肌肉、肌腱、脂
The U.S. Food and Drug Administration (FDA) approved Halaven (eribulin mesylate, eribulin mesylate) on January 28 for the treatment of patients who can not be surgically resected or who have advanced (metastatic) liposarcoma and are approved For patients who have received anthracycline-containing chemotherapy. The director of the Office of Hematology and oncology products at the FDA Center for Drug Evaluation and Research says Halaven is the first drug approved for liposarcoma that has been shown to improve patient survival. Clinical review data reviewed by the FDA show that Halaven prolongs overall survival by about seven months and provides patients with clinically meaningful drugs. Soft tissue sarcoma (STS) is a disease in which cancer cells grow in soft tissues in the body, including muscles, tendons, lipids